최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Neuropharmacology, v.166, 2020년, pp.107678 -
Chao, Po-Kuan (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes) , Chang, Hsiao-Fu (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes) , Chang, Wan-Ting (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes) , Yeh, Teng-Kuang (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes) , Ou, Li-Chin (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes) , Chuang, Jian-Ying (The PhD Program for Neural Regenerative Medicine, Taipei Medical University) , Tsu-An Hsu, John (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes) , Tao, Pao-Luh (Center for Neuropsychiatric Research, National Heath Research Institutes) , Loh, Horace H. (Department of Pharmacology, University of Minnesota Medical School) , Shih, Chuan , Ueng, Shau-Hua , Yeh, Shiu-Hwa
Abstract There is unmet need to design an analgesic with fewer side effects for severe pain management. Although traditional opioids are the most effective painkillers, they are accompanied by severe adverse responses, such as respiratory depression, constipation symptoms, tolerance, withdrawal, an...
Anesthesiology Al-Hasani 115 1363 2011 10.1097/ALN.0b013e318238bba6 Molecular mechanisms of opioid receptor-dependent signaling and behavior
Science Bohn 286 2495 1999 10.1126/science.286.5449.2495 Enhanced morphine analgesia in mice lacking beta-arrestin 2
Br. J. Pharmacol. Calo 129 1261 2000 10.1038/sj.bjp.0703219 Pharmacology of nociceptin and its receptor: a novel therapeutic target
Br. J. Anaesth. Calo 121 1105 2018 10.1016/j.bja.2018.06.024 Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic
Nature Cao 392 390 1998 10.1038/32897 Primary afferent tachykinins are required to experience moderate to intense pain
Anesthesiology: J. Am. Soc. Anesthesiologists Chao 126 952 2017 10.1097/ALN.0000000000001568 1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: a novel opioid receptor agonist with less accompanying gastrointestinal dysfunction than morphine
J. Neurosci. Methods Chaplan 53 55 1994 10.1016/0165-0270(94)90144-9 Quantitative assessment of tactile allodynia in the rat paw
Eur. J. Med. Chem. Chen 126 202 2017 10.1016/j.ejmech.2016.09.003 Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists
J. Pharmacol. Exp. Ther. Cremeans 343 72 2012 10.1124/jpet.112.194308 Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates
Cell. Mol. Neurobiol. Curto-Reyes 28 981 2008 10.1007/s10571-008-9272-3 Local loperamide inhibits thermal hyperalgesia but not mechanical allodynia induced by intratibial inoculation of melanoma cells in mice
Anesthesiology Dahan 126 697 2017 10.1097/ALN.0000000000001529 Respiratory effects of the nociceptin/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers
Nat. Commun. Devilliers 4 2013 10.1038/ncomms3941 Activation of TREK-1 by morphine results in analgesia without adverse side effects
J. Pharmacol. Exp. Ther. DeWire 344 708 2013 10.1124/jpet.112.201616 A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine
Proc. Natl. Acad. Sci. U.S.A. Ding 113 E5511 2016 10.1073/pnas.1605295113 A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates
Br. J. Pharmacol. Ding 172 3302 2015 10.1111/bph.13124 Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates
Sci. Transl. Med. Ding 10 2018 10.1126/scitranslmed.aar3483 A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates
Neurosci. Lett. Ebert 187 165 1995 10.1016/0304-3940(95)11364-3 Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord
J. Biol. Chem. El Kouhen 274 9207 1999 10.1074/jbc.274.14.9207 The absence of a direct correlation between the loss of [d-Ala2,MePhe4,Gly5-ol]Enkephalin inhibition of adenylyl cyclase activity and agonist-induced μ-opioid receptor phosphorylation
Curr. Drug Targets Feng 13 230 2012 10.2174/138945012799201612 Current research on opioid receptor function
Eur. J. Pharmacol. Fischetti 614 50 2009 10.1016/j.ejphar.2009.04.054 Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24
Am. J. Pathol. Goldsmith 179 673 2011 10.1016/j.ajpath.2011.04.032 Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling
J. Med. Chem. Goto 49 847 2006 10.1021/jm0509851 Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity
Nat. Commun. Grundmann 9 2018 10.1038/s41467-017-02661-3 Lack of beta-arrestin signaling in the absence of active G proteins
J. Pharmacol. Exp. Ther. Han 348 316 2014 10.1124/jpet.113.209866 Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide
J. Pharmacol. Exp. Ther. Khroyan 336 952 2011 10.1124/jpet.110.175620
J. Pharmacol. Exp. Ther. Khroyan 331 946 2009 10.1124/jpet.109.156711 Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/μ-Opioid receptor agonists
J. Pharmacol. Exp. Ther. Khroyan 320 934 2007 10.1124/jpet.106.111997 SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/μ-Opioid receptor partial agonist: analgesic and rewarding properties in mice
Br. J. Pharmacol. Kilkenny 160 1577 2010 10.1111/j.1476-5381.2010.00872.x Animal research: reporting in vivo experiments: the ARRIVE guidelines
Neuropsychopharmacology Ko vol. 34 2088 2009 10.1038/npp.2009.33 Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys
Yonsei Med. J. Lee 46 252 2005 10.3349/ymj.2005.46.2.252 Behavioral characteristics of a mouse model of cancer pain
Nucleic Acids Res. Lee 42 13012 2014 10.1093/nar/gku1016 Morphine drives internal ribosome entry site-mediated hnRNP K translation in neurons through opioid receptor-dependent signaling
Eur. J. Pharmacol. Liao 606 84 2009 10.1016/j.ejphar.2009.01.036 1-Benzyl-N-[3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (Compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices
ACS Chem. Neurosci. Lin 4 214 2013 10.1021/cn300124f The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability
J. Pharmacol. Exp. Ther. Linz 349 535 2014 10.1124/jpet.114.213694 Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist
Anesthesiology Linz 126 708 2017 10.1097/ALN.0000000000001530 Opioid-type respiratory depressant side effects of cebranopadol in rats are limited by its nociceptin/orphanin FQ peptide receptor agonist activity
J. Biol. Chem. Macey 281 34515 2006 10.1074/jbc.M604278200 Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons
Biochim. Biophys. Acta Rev. Canc. Mancino 1816 105 2011 10.1016/j.bbcan.2011.04.005 The neuronal influence on tumor progression
Nature Manglik 537 185 2016 10.1038/nature19112 Structure-based discovery of opioid analgesics with reduced side effects
J. Neurosci. Mathews 28 12183 2008 10.1523/JNEUROSCI.2326-08.2008 A novel Gβγ-subunit inhibitor selectively modulates μ-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence
Int. Rev. Neurobiol. Nash 118 105 2014 10.1016/B978-0-12-801284-0.00005-1 Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors
Therapeut. Clin. Risk Manag. Nersesyan 3 381 2007 Current aproach to cancer pain management: availability and implications of different treatment options
J. Cereb. Blood Flow Metab. Pardridge 32 1959 2012 10.1038/jcbfm.2012.126 Drug transport across the blood-brain barrier
Acta Anaesthesiol. Taiwanica Pasternak 49 21 2011 10.1016/j.aat.2010.12.008 Mu opioid receptors in pain management
Br. J. Pain Pathan 6 11 2012 10.1177/2049463712438493 Basic opioid pharmacology: an update
The Lancet Portenoy 353 1695 1999 10.1016/S0140-6736(99)01310-0 Management of cancer pain
J. Pharmacol. Exp. Ther. Raehal 314 1195 2005 10.1124/jpet.105.087254 Morphine side effects in beta-arrestin 2 knockout mice
Pharmacol. Res. Perspect. Rizzi 4 2016 10.1002/prp2.247 Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist
J. Pharmacol. Exp. Ther. Ross 327 561 2008 10.1124/jpet.108.143438 Morphine tolerance in the mouse ileum and colon
J. Neurosci. Rusin 17 6565 1997 10.1523/JNEUROSCI.17-17-06565.1997 κ-Opioid receptor activation modulates Ca2+Currents and secretion in isolated neuroendocrine nerve terminals
Addict. Sci. Clin. Pract. Savage 4 4 2008 10.1151/ascp08424 Challenges in using opioids to treat pain in persons with substance use disorders
Nat. Neurosci. Schuller 2 151 1999 10.1038/5706 Retention of heroin and morphine-6β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1
EMBO J. Schulz 23 3282 2004 10.1038/sj.emboj.7600334 Morphine induces terminal μ-opioid receptor desensitization by sustained phosphorylation of serine-375
J. Pharmacol. Exp. Ther. Sobczak 348 401 2014 10.1124/jpet.113.209825 Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases
J. Biol. Chem. Tan 284 6270 2009 10.1074/jbc.M806742200 p38 MAPK and β-arrestin 2 mediate functional interactions between endogenous μ-opioid and α(2A)-adrenergic receptors in neurons
J. Pharmacol. Exp. Ther. Toll 331 954 2009 10.1124/jpet.109.157446 Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/μ-opioid receptor ligands: implications for therapeutic applications
Addict. Biol. Tzschentke 23 1010 2018 10.1111/adb.12550 Limited potential of cebranopadol to produce opioid-type physical dependence in rodents
Pain Pract. Tzschentke 17 1032 2017 10.1111/papr.12558 Antihyperalgesic, antiallodynic, and antinociceptive effects of cebranopadol, a novel potent nociceptin/orphanin FQ and opioid receptor agonist, after peripheral and central administration in rodent models of neuropathic pain
Neuropsychopharmacology Urs 36 551 2011 10.1038/npp.2010.186 A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice
Proc. Natl. Acad. Sci. U.S.A. Wang 109 6325 2012 10.1073/pnas.1200130109 Morphine activates neuroinflammation in a manner parallel to endotoxin
Br. J. Pharmacol. Wang 173 856 2016 10.1111/bph.13394 Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4
Pharmacol. Rev. Williams 65 223 2013 10.1124/pr.112.005942 Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
※ AI-Helper는 부적절한 답변을 할 수 있습니다.